Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non‐T790M mutations after progression on first‐line EGFR‐tyrosine kinase inhibitors

BACKGROUND: The purpose of this study was to compare the effects of pemetrexed and carboplatin plus bevacizumab (PC + B) versus pemetrexed and carboplatin (PC) in lung adenocarcinoma patients with EGFR non‐T790M mutations after progression on first‐line EGFR‐tyrosine kinase inhibitors (TKIs). METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Zhansheng, Zhang, Yu, Yang, Yinli, Yue, Zhensong, Pan, Zhanyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119611/
https://www.ncbi.nlm.nih.gov/pubmed/30027579
http://dx.doi.org/10.1111/1759-7714.12814

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119611/
https://www.ncbi.nlm.nih.gov/pubmed/30027579
http://dx.doi.org/10.1111/1759-7714.12814

Ejemplares similares